Berlin, Germany

Alfredo Zurlo

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Alfredo Zurlo

Introduction

Alfredo Zurlo is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the treatment of viral infections. With a total of four patents to his name, his work has the potential to impact the medical community profoundly.

Latest Patents

Zurlo's latest patents include innovative methods for treating retroviral infections. One of his inventions relates to a non-coding sequence of deoxyribonucleic acids that comprises at least one sequence motif NNCGNN. This invention is particularly relevant for the treatment of viral infections, as it is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors. Another significant patent involves a combination of a T-cell regulator and a non-coding immunomodulating DNA, which is aimed at treating various diseases.

Career Highlights

Throughout his career, Alfredo Zurlo has worked with prominent companies in the biotechnology sector. Notable among these are Mologen AG and Gilead Sciences, Inc. His experience in these organizations has contributed to his expertise and innovative capabilities in the field.

Collaborations

Zurlo has collaborated with several professionals in his field, including Matthias Schroff and Manuel Schmidt. These collaborations have likely enhanced his research and development efforts, leading to his successful patent applications.

Conclusion

Alfredo Zurlo's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…